Novartis data at ASCO and EHA showcase bold approaches to reimagine cancer and blood disorders through multiple therapeutic platforms

NEXT STORY
Smile Direct Club Appoints New Members to Clinical Advisory Board
PREV STORY
New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ for Severe Hemoglobinopathies Accepted for Oral Presentation at the 25th European Hematology Association (EHA) Congress
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

AXIM® Biotechnologies’ Manufacturing Partner Empowered Diagnostics Files for Approval for Use of Rapid COVID-19 Neutralizing Antibody Test in Whole Blood at Point-of-Care Locations in Canada and the EU

author_avatar
NASDAQ Market News

UDPATE – Relay Medical and Fio Corporation Launch Mobile COVID-19 Testing and Tracking Platform

author_avatar
NASDAQ Market News

Innate Pharma in-licenses OREGA biotech’s first-in-class anti-CD39 checkpoint inhibitor program

This program, currently in preclinical development, aims at developing an anti-CD39 mAb; Targeting the ...

author_avatar
NASDAQ Market News